Palisade Bio Highlights PALI-2108 Clinical And Translational Findings In 5 ACG 2026 Presentations

Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development

Two presentations selected for ACG Presidential Poster Awards, a distinction received by approximately 5% of accepted abstracts

Microbiome and transcriptomic analyses support the delivery platform and a potential precision medicine approach

Denver, CO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation oral therapies for immune-mediated diseases, today announced clinical and translational findings featured in five poster presentations at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee. The findings strengthen the scientific rationale for the Company’s ongoing Phase 2 development of PALI-2108, its investigational oral, locally activated PDE4 inhibitor prodrug, in ulcerative colitis (UC) and Crohn’s disease (CD).